Accuray Inc. ARAY
Medical/Dental Instruments · IPO 2007 · data as of November 13, 2026
Accuray Inc. (ARAY) is a healthcare company listed in the US with a market value of about $8M. In the twelve months to September 30, 2026 it had revenue of $395M and net income of -$17M, a net margin of -4.4%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is value (1/5); the weakest is track record (0/5).
Key numbers: 5-year revenue growth of 0% a year, a 5-year average ROIC of -1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 248% above the current price.
About Accuray
Accuray is listed in the US and classified in medical/dental instruments, IPO year 2007. Revenue went from $380M in 2015 to $402M in 2026, growth of about 0.5% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 29% over three years (dilution for shareholders). It spends 9% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- Strong R&D investment or growth above 20%
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $395M | $402M | $459M | $447M | $448M | $430M | $396M | $383M | $419M | $405M | $383M |
| Net income | -$17M | -$49M | -$2M | -$16M | -$9M | -$5M | -$6M | $4M | -$16M | -$24M | -$30M |
| Free cash flow | -$27M | -$13M | -$1M | -$16M | $3M | -$7M | $36M | -$5M | -$34M | $12M | -$5M |
| EPS (diluted) | $-5.60 | $-16.00 | $-0.80 | $-6.40 | $-4.00 | $-2.40 | $-2.80 | $1.60 | $-7.60 | $-11.20 | $-14.40 |
| Net margin | -4.4% | -12.2% | -0.4% | -3.5% | -2.1% | -1.2% | -1.6% | 1.0% | -3.9% | -5.9% | -7.7% |
| ROIC | — | -9.3% | 2.4% | 0.2% | 0.7% | 2.5% | 6.6% | 3.0% | 0.2% | -1.7% | -3.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Accuray stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 248% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Accuray pay a dividend?
Not currently.
Is Accuray a good stock to buy?
We do not give buy or sell advice. Accuray scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.